Emerging issues in probiotic safety: 2023 perspectives.

Merenstein D, Pot B, Leyer G, Ouwehand AC, Preidis GA, Elkins CA, Hill C, Lewis ZT, Shane AL, Zmora N, Petrova MI, Collado MC, Morelli L, Montoya GA, Szajewska H, Tancredi DJ, Sanders ME. · 2023

Read Emerging issues in probiotic safety: 2023 perspectives. by Merenstein D, Pot B, Leyer G, Ouwehand AC, Preidis GA, Elkins CA, Hill C, Lewis ZT, Shane AL, Zmora N, Petrova MI, Collado MC, Morelli L, Montoya GA, Szajewska H, Tancredi DJ, Sanders ME. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10026873.txt.

Introduction

Merenstein and many co-authors review emerging questions about probiotic safety in a 2023 paper. Probiotics are live microbes sold for gut and general health. Healthy shoppers use them widely, and clinics use them with patients who are frail or very ill. Most use looks safe, but rare harms have been reported.

The authors survey known and possible risks as new strains reach new groups of users. They call for clearer labels, better tracking of harms, and care with high-risk patients. The paper is a measured guide for clinicians and makers alike.

Catalog record

CREATORMerenstein D, Pot B, Leyer G, Ouwehand AC, Preidis GA, Elkins CA, Hill C, Lewis ZT, Shane AL, Zmora N, Petrova MI, Collado MC, Morelli L, Montoya GA, Szajewska H, Tancredi DJ, Sanders ME.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE89 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10026873

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Emerging issues in probiotic safety: 2023 perspectives By Daniel Merenstein, Bruno Pot, Gregory Leyer, Arthur C Ouwehand, Geoffrey A Preidis, Christopher A Elkins, Colin Hill, Zachery T Lewis, Andi L Shane, Niv Zmora, Mariya I Petrova, Maria Carmen Collado Published in: Gut Microbes DOI: 10.1080/19490976.2023.2185034 ABSTRACT ABSTRACT Probiotics are used for both generally healthy consumers and in clinical settings. However, theoretical and proven adverse events from probiotic consumption exist. New probiotic strains and products, as well as expanding use of probiotics into vulnerable populations, warrants concise, and actionable recommendations on how to work toward their safe and effective use. The International Scientific Association for Probiotics and Prebiotics convened a meeting to discuss and produce evidence-based recommendations on potential acute and long-term risks, risks to vulnerable populations, the importance for probiotic product quality to match the needs of vulnerable populations, and the need for adverse event reporting related to probiotic use. The importance of whole genome sequencing, which enables determination of virulence, toxin, and antibiotic resistance genes, as well as clear assignment of species and strain identity, is emphasized. We present recommendations to guide the scientific and medical community on judging probiotic safety. KEYWORDS: Probiotic, safety, next-generation probiotics, antibiotic resistance, microbiome, microbiota, genome sequencing, live biotherapeutic products, International Scientific Association for Probiotics and Prebiotics, ISAPP BACKGROUND Probiotics have been defined as ‘live microorganisms that, when administered in adequate amounts, confer a health benefit on the host’, a definition that was a grammatical edit of a previous FAO expert consultation.1 In the last 20 years, the number and quality of clinical trials assessing the health benefits of probiotics has grown substantially. Advances in efficacy measurement have been integral to the growth of the category. As is the case for any intervention, it is important not just to measure benefits but also to characterize risks. Early probiotics were associated with traditional uses in naturally fermented food products and thus not viewed as drugs, perhaps leading to less attention in earlier probiotic research to adverse event (AE) monitoring and reporting. Among the general population and in patients who are not immunocompromised or severely debilitated, acute safety issues appear to be minor, especially when considering the large global use of probiotics in foods and nutritional supplements.2–5 Further, more recent clinical trials reflect much improved reporting of AEs. As is the case with most interventions, though, longer-term safety endpoints are seldom tracked by trialists. As live products, there are theoretical risks of long-term impact on microbiota, immunity, cardiometabolic, and other physiological parameters that deserve further discussion. The topic of probiotic safety has been addressed by several groups.6–10 A foundational initiative by the European Food Safety Authority established the Qualified Presumption of Safety approach for live microorganisms used in foods.11 This guidance is useful for recognizing microbial species with a history of safe use in foods. Pariza and colleagues12 proposed a 15-step decision tree to guide safety evaluations for products that lack an established history of safe use. An important paper modeled how to evaluate safety at the strain level, applied to the widely used Enterococcus faecium SF68.13 Roe and colleagues14 summarized best practices for assessing the quality and safety of probiotics, noting diverse regulatory frameworks utilized in different global regions. A highly cited and thorough review of probiotic safety was conducted by the Southern California Evidence-based Practice Center, sponsored by the Agency for Healthcare Research and Quality.5 The review conducted in 2009 identified 622 studies, of which only 235 (37%) provided nonspecific statements about safety. Hempel et al. concluded that, from the available evidence, although interventions and AEs were poorly documented, there was no statistically significant increase of the relative risk (RR) of the overall number of experienced AEs (RR 1.00; 95% confidence interval: 0.93, 1.07, p = 0.999) associated with probiotic use. Over the 12 years since the Hempel and colleagues review was published, improved knowledge of the microbiota and probiotics warrants a new look at the question of probiotic safety. This paper is the result of a discussion of an expert panel convened by the International Scientific Association for Probiotics and Prebiotics (ISAPP) at their 2022 annual meeting. ISAPP is a non-profit organization dedicated to advancing the science of probiotics and prebiotics. The assembled panel considered emerging issues pertaining to the safety of probiotics that warrant reconsideration as new data arise (Figure 1). Such issues include potential acute and long-term risks, the need for long-term studies, considerations for vulnerable target populations, probiotic product quality, and the importance of robust reporting of adverse events. The authors met for a half-day to discuss information presented by some panelists leading to a general agreement on key conclusions and recommendations. Individuals authored sections related to their expertise and that text was compiled, reviewed, and edited by all authors. [Figure: Factors for safety assessment of probiotics. AR, antibiotic resistance; GMP, good manufacturing requirements; MIC, minimum inhibitory concentration; Next-gen, next-generation.] FUNDAMENTALS OF PROBIOTIC SAFETY Concerns related to the safety of probiotic organisms have been raised by clinicians, researchers, and policymakers.15–17 These may be broadly characterized into concerns pertaining to the probiotic strain, product quality, or probiotic administration. A foundation to assessing the safety of any given probiotic strain is a complete genome sequence. This allows assignment of the strain to a given taxonomic group, enabling review of published risks associated with the species. A full genome sequence also allows strain-level identification, which can be important for tracking the strain during production and to investigate etiology of suspected infections. Further, the genome can be interrogated for any genes of concern, including toxigenicity, pathogenicity, or antibiotic resistance (AR). As discussed in more detail below, one concern is the theoretical situation in which probiotic-borne AR genes could be transferred to resident potential pathogens, other microbes harbored by the host, and/or environmental microbes, thereby increasing the ecological pool of antimicrobial resistance genes.15–17 Scientists are still evaluating the real transfer risk and the clinical and public health implications of such transfer. Some phenotypic testing is also a component of assessing safety of the probiotic strain. Issues related to safety pertaining to formulation of probiotic products include the need to establish purity, potency (the quantity of live microbes delivered), and composition of the final product. Further, probiotic products must undergo adequate testing – adapted to the intended use – for potential contaminants.15–17 Of particular concern is the presence of unwanted live microbial contaminants. Since probiotics are designed to be administered as live microbes, contamination with pathogenic or potentially pathogenic microbes is a greater risk than for products that undergo an intentional sterilization process. Testing specifications can be tailored for products, with products destined for more vulnerable populations undergoing testing that is more stringent than those used for the general population (Table 1). Microbial contamination of the final product and the presence of allergens or other contaminants are also concerns, but no more so for probiotics than for any other intervention. [Table: Example testing requirements for a given probiotic developed for different product types and target populations. Note that stringent testing requirements can be imposed for products targeted for the most vulnerable populations.] The manner in which the probiotic is given or taken must also be safe. This constitutes safe administration of a properly designed product to

Read the complete text